U.S. federal health agencies on Tuesday called for an immediate hiatus for the Johnson & Johnson single-dose COVID-19 vaccine amid reports of clotting problems.
The announcement came after six cases of a rare and serious type of blood clot that developed about two weeks after the vaccine was given were discovered.
The Centers for Disease Control and Prevention (CDC) “will convene a meeting of the Advisory Committee on Immunization Practices (ACIP) on Wednesday to further examine these cases and assess their potential importance,” the CDC and the Food and Drug Administration said ( FDA). in a joint statement, ABC News reported.
The FDA will also review this scan as it is investigating cases as well.
“Until this process is complete, we recommend a pause in the use of this vaccine as an excess of caution,” the statement continued.
âThis is important, in part, to ensure that the healthcare provider community is aware of the potential of these adverse events and can plan for appropriate recognition and management due to the unique treatment required with this type of blood clot. “
The news comes as the United States tries to outsmart new strains of the virus to vaccinate as many of the nation’s population as possible.
The United States has so far recorded more than 31 million cases of coronavirus infection and nearly 563,000 related deaths, according to a current tally from Johns Hopkins University in Maryland.
In Europe, the AstraZenaca vaccine has also raised concerns about reported blood clots.
The Anadolu Agency website contains only a portion of the stories offered to subscribers in the AA News Distribution System (HAS), and in summary form. Please contact us for subscription options.